A Phase 3 interventional study of Bimekizumab in Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 47 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.
Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 7th largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 3, and was the 9th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 210 across the 14 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 5 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
18 studies in Arthritis, Psoriatic by UCB S.A.: 2 open now, 3 under way, 1 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 18 studies in Arthritis, Psoriatic by UCB S.A., this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2019, is one of 9 in phase 3, and was the 13th registered.
UCB S.A.’s Arthritis, Psoriatic studies by the year they started, since 2010.
1 of the studies testing bimekizumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 18 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Subjects are not permitted to enroll in DV0004 if any of the PA0012 [NCT04009499] study exclusion criteria are met
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the prefilled safety syringe (SS).
Drug: Bimekizumab
Study participants randomized to this arm will receive assigned bimekizumab dose regimen using the auto-injector (AI).
Drug: Bimekizumab
Study participants will receive bimekizumab at pre-specified time points.
Also known as: UCB4940, BKZ
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).
Time frame: Week 4
Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Baseline
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).
Time frame: Baseline
The study started to enroll study participants in Aug 2019 and concluded in Nov 2020. This study is a substudy to PA0012 (NCT04009499).
| Milestone | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W |
|---|---|---|
| Started | 107 | 107 |
| Completed | 106 | 107 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-safety syringe (SS) or the bimekizumab-auto-injector (AI) which shows that the investigational medicinal product (IMP) was delivered completely (ie, container is empty), and - No Adverse Device Effects (ADEs) that would preclude continued use of the device for self-injection (ie, no serious ADEs (SADEs) and/or ADEs leading to withdrawal).
| percentage of participants | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W |
|---|---|---|
| Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Week 4 | 100 (97.2 to 100) | 100 (97.2 to 100) |
Safe and effective self-injection was evaluated by the study personnel and was defined as: - Complete dose delivery: Participant self-injected the complete dose of bimekizumab as confirmed by a visual inspection of the bimekizumab-SS or the bimekizumab-AI which shows that the IMP is delivered completely (ie, container is empty), and - No ADEs that would preclude continued use of the device for self-injection (ie, no SADEs and/or ADEs leading to withdrawal).
| percentage of participants | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W |
|---|---|---|
| Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab Safety Syringe (BKZ-SS) or the Bimekizumab Auto-injector (BKZ-AI) at Baseline | 100 (97.2 to 100) | 100 (97.2 to 100) |
Collected over From Baseline up to Week 5. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BKZ-SS-1mL 160 mg Q4W | 0/107 (0%) | 0/107 (0%) | 0/107 (0%) |
| BKZ-AI-1mL 160 mg Q4W | 0/107 (0%) | 0/107 (0%) | 0/107 (0%) |
Baseline Characteristics refer to the Safety Set (SS) consisted of all study participants who received at least 1 dose of bimekizumab by the indicated self-injection investigational device presentation (bimekizumab-SS-1mL \[SS-s\] and bimekizumab-AI-1mL \[SS-a\]).
| Age, Categorical(Participants) | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 94 | 91 | 185 |
| >=65 years | 13 | 16 | 29 |
| Age, Continuous(years) | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W | Total |
|---|---|---|---|
| Mean | 48.3 ± 13.2 | 51.5 ± 11.9 | 49.9 ± 12.6 |
| Sex: Female, Male(Participants) | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W | Total |
|---|---|---|---|
| Female | 54 | 54 | 108 |
| Male | 53 | 53 | 106 |
| Race/Ethnicity, Customized(Participants) | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W | Total |
|---|---|---|---|
| White | 106 | 107 | 213 |
| Other/Mixed | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | BKZ-SS-1mL 160 mg Q4W | BKZ-AI-1mL 160 mg Q4W | Total |
|---|---|---|---|
| Not Hispanic or Latino | 106 | 107 | 213 |
| Hispanic or Latino | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2019 to primary completion in Nov 2020, 14 months.
Results were first posted in Nov 2023, 3 years after primary completion. A results delay was requested in Nov 2021.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 14 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab